American Well Corp
No SEC Form 4 filings for $AMWL in the last 30 days.
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
Analyst estimates cited by FactSet show American Well Corp’s 12-month average price target increased from $8.50 to $11.58. The range is $7.50 to $16. Based on the Aug. 4 close, the target implies about 11% upside. The consensus rating remains “Hold” (1 Buy, 7 Hold, 0 Sell) across 8 analysts.
American Well Corp (AMWL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001393584 false 0001393584 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08,
Over the past 7 days, alphai's AI scored 2 news stories mentioning AMWL (American Well Corp). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent AMWL coverage spans market movers, insider activity and financial news.
The trade is profitability improvement versus declining revenue, with Q3 guidance setting the near-term ceiling.
The article is a sell-side target revision story, not a fundamental company disclosure. It can still move near-term sentiment and positioning if traders treat PT changes as a proxy for improving outlook.
Board class rebalancing is administrative and explicitly not due to disagreements, so near-term fundamentals should be largely unchanged.
The move appears sentiment-driven, but the disclosed revenue outlook implies a fundamental headwind.
Near-term momentum is supported by platform validation and insurer-related agreement, but the 2026 revenue range is below 2025.
alphai scores every news story that mentions AMWL with an AI model for sentiment and relevance, and aggregates insider trades from American Well Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readAnalyst estimates cited by FactSet show American Well Corp’s 12-month average price target increased from $8.50 to $11.58. The range is $7.50 to $16. Based on the Aug. 4 close, the target implies about 11% upside. The consensus rating remains “Hold” (1 Buy, 7 Hold, 0 Sell) across 8 analysts.
1 min readAmerican Well Corp (AMWL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001393584 false 0001393584 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08,
2 min readBiotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
7 min readBiotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.
5 min readAmerican Well Corp (AMWL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001393584 0001393584 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
2 min readHIRSCHHORN MARK (Chief Financial Officer) sold 10,761 shares of American Well Corp (AMWL) at $9.74 ($0.10M total) on 2026-06-01.
1 min readGotlib Phyllis (President, International) sold 3,573 shares of American Well Corp (AMWL) at $9.74 on 2026-06-01.
2 min readMcNeice Paul Francis (Chief Accounting Officer) sold 112 shares of American Well Corp (AMWL) at $9.74 on 2026-06-01.
2 min readAmerican Well Corporation (AMWL) reported its first-quarter 2026 results, showing shrinking losses despite a year-over-year revenue decline. The company achieved $54.9 million in revenue, a net loss of $10.3 million, and an adjusted EBITDA loss of $3.1 million. Amwell reaffirmed its full-year 2026 revenue guidance and updated its adjusted EBITDA outlook, maintaining its target for positive cash flow from operations in Q4 2026.
3 min read
